Find insight on Samsung Biologics, China biotech companies and more in the latest Market Talks covering Health Care.

Biocon Biologics receives marketing authorisation from the European Commission for two Denosumab biosimilars, Vevzuo and Evfraxy, for treating bone diseases and related conditions ...

The real-world evidence solutions market is largely driven by the increasing prevalence of chronic diseases and their impact on real-world healthcare ...

Who owns Samsung? A look at the company's corporate structure, key shareholders, and how the Lee family still controls the ...

Samsung Biologics is also exploring partnerships with overseas hospitals to broaden its patient-derived organoid bank and is considering future data licensing models. While its organoid unit may start ...

Samsung Biologics launches drug screening services, Samsung Organoids: Incheon, S. Korea Tuesday, June 17, 2025, 12:00 Hrs [IST] Samsung Biologics, a leading contract development ...

Samsung Organoids to provide data-driven analysis of candidate moleculesSamsung Biologics expands service scope to include preclinical researchINCHEON, South Korea, June 15, 2025 /PRNewswire ...

Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced the launch of Samsung Organoids – advanced drug screening services to support ...

Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced the launch of Samsung Organoids – advanced drug screening services to ...

Samsung Bioepis was a joint venture co-founded by Samsung Biologics and U.S. biotechnology company Biogen in 2012, with Samsung Biologics holding an 85% stake and Biogen holding 15%.

The spin-off is expected to boost the valuation of not only the two biotech firms but also their largest shareholder Samsung C&T, which has a 43.06 percent stake in Biologics.

In a regulatory filing, Biologics announced that it will spin off a business division overseeing its subsidiary and new investments to create Samsung Epis Holdings. The holding company will then ...